exagamglogene autotemcel
exagamglogene autotemcel: sourced relationships with 1 company · 7 clinical trials tracked.
exagamglogene autotemcel evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
How could exagamglogene autotemcel → EDIT affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Editas Medicine, Inc. (EDIT) Sickle cell disease (SCD) and transfusion-dependent beta tha… | Approved |
Clinical Trial Registry Records (7)
A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects With Severe Sickle Cell Disease, βS/βC Genotype
Primary endpoint: Proportion of Participants with an Average Fetal Hemoglobin (HbF) Greater Than or Equal To (>=) 20 percent (%) on or After 6 Months
A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease
Primary endpoint: Fetal Hemoglobin (HbF) Concentration Over Time
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent β-Thalassemia
Primary endpoint: Proportion of Participants who Achieve Transfusion Independence for at Least 12 Consecutive Months (TI12)
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease
Primary endpoint: Proportion of Participants who do not Have any Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months (VF12)
A Long-term Follow-up Study of Subjects With β-thalassemia or Sickle Cell Disease Treated With Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)
Primary endpoint: New malignancies
A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease
Primary endpoint: Percentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel Infusion
A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent β-Thalassemia
Primary endpoint: Proportion of participants achieving transfusion independence for at least 12 consecutive months (TI12)
Frequently asked questions
Which companies have sourced relationships with exagamglogene autotemcel?
exagamglogene autotemcel has dated SEC/FDA relationship records for Editas Medicine, Inc..
How many clinical trials involve exagamglogene autotemcel?
BioSniper tracks 7 clinical trials involving exagamglogene autotemcel.